Interferon beta-1a
Drugserum free Avonex given IM once a week
Other names: Avonex
NCT Number: NCT00912860
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other inclusion and exclusion criteria apply as per protocol
serum free Avonex given IM once a week
Other names: Avonex
Time frame: Study duration is 20 months
Time frame: The study duration is 20 months
Looking for future studies?
Notify MeBiogen
Industry
A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04721717
Amyotrophic Lateral Sclerosis, Autoimmune Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05835622
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Saint-Genis-Laval, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT03599245
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Buenos Aires, Argentina
View Trial DetailsNCT07840924
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Arnhem, Netherlands
View Trial Details